Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Azacyclonol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.49 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.96 |
| ▸ | MEN1 | O00255 | 1/20 | 0.96 |
| ▸ | SCN1A | P35498 | 1/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.96 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.96 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azacyclonol SCHEMBL241817 | 0.98 | HRH1 (1.00) | HRH1CYP2D6LMNAMEN1SCN1A | |
| Azacyclonol SCHEMBL1890138 | 0.96 | HRH1 (0.96) | HRH1CYP2D6LMNAMEN1SCN1A | |
| Azacyclonol SCHEMBL1648657 | 0.94 | HRH1 (0.93) | HRH1CYP2D6LMNAMEN1SCN1A | |
| Azacyclonol SCHEMBL27517195 | 0.90 | HRH1 (0.83) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL11395372 | 0.90 | CYP2D6 (0.83) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL11831606 | 0.88 | HRH1 (0.81) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL7328353 | 0.88 | CYP2D6 (0.81) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL11832155 | 0.88 | CYP2D6 (0.81) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL11835095 | 0.88 | CYP2D6 (0.81) | HRH1CYP2D6LMNAMEN1SCN1A | |
| SCHEMBL13923571 | 0.88 | HRH1 (0.81) | HRH1CYP2D6LMNAMEN1SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1260505-B1 | A process for the preparation of 4-[1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl]-alpha, alpha-dimethylbenzeneacetic acid | DIPHARMA SPA (IT) | 2005-03-09 | — | — | EP | disclosed |
| US-6815549-B2 | REACTING AN ACETYLINIC COMPOUND CONTAINING HALOGEN OR SULFONATE GROUP WITH A 4-((4-HYDROXYDIPHENYLMETHYL)-1-PIPERIDINE) TO FORM ANINTERMEDIATE, CONDENSING IT WITH AN DIMETHYLBENZENE ACETATES | DINAMITE DIPHARMA S.P.A. (IT) | 2004-11-09 | — | — | US | disclosed |
| US-20020198233-A1 | Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethly)-1-piperidinyl]-butyl]-alpha,alpha-dimethylbenzeneacetic acid | DINAMITE DIPHARMA S.P.A. ABBREVIATED DIPHARMA S.P.A. (IT) | 2002-12-26 | — | — | US | disclosed |
| EP-1260505-A1 | A process for the preparation of 4-[1-hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)-butyl]-alpha, alpha-dimethylbenzeneacetic acid | Dinamite Dipharma S.p.A. (IT) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198233-A1 | Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethly)-1-piperidinyl]-butyl]-alpha,alpha-dimethylbenzeneacetic acid | P4HA1, CYP4X1, HRH2 | CHRM3 2280/4885SIGMAR1 459/4885HRH1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.